Findings From LUSTRE Trial Confirm SBRT a ‘Good Alternative’ to Conventional Radiation for Inoperable Lung Cancer, Says Expert


Data from the phase 3 LUSTRE trial indicated that stereotactic body radiotherapy is a safe and effective alternative to conventional radiation for use in patients with stage I medically-inoperable non-small lung cancer, according to an expert from Juravinski Cancer Centre in Canada.

Stereotactic body radiotherapy (SBRT) may serve as a safe and effective alternative to conventional hypofractionated radiotherapy (CRT) to treat patients with stage I inoperable non-small cell lung cancer, according to Anand Swaminath, MD.

During the 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting, Swaminath spoke with CancerNetwork® about data from the phase 3 LUSTRE trial (NCT01968941), which he said supports the fact that more and more oncologists are using SBRT to treat their patients with early-stage inoperable non-small cell lung cancer.

Investigators in the LUSTRE trial compared SBRT with CRT to assess local disease control, which was defined as the absence of primary tumor or marginal failure. The 3-year local control rate for SBRT and CRT, respectively, was 87.6% and 81.2% (HR, 0.61; 95% CI, 0.31-1.20; P = .15).

Swaminath, an associate professor, clinician scientist, and radiation oncologist at Juravinski Cancer Centre in Ontario, Canada, concluded that the findings provide treating physicians guidance on how to best treat patients they consider at greater risk for adverse events.


Stereotactic radiation for both central and peripheral lung cancer is safe. It's effective. It's probably a good alternative to conventional radiation, even if it's done in 15 days. There is an opportunity here to evaluate the patients with central tumors more robustly to ensure that the community is comfortable treating them safely. That reaffirms our practice, because a lot of people are doing stereotactic radiation already, so it reaffirms that what we're doing is safe and effective. But it also gives us guidance on how we can treat those patients [for] whom we're considering that there might be a higher risk of toxicity. All in all, I think it was a trial that answered a lot of good questions and taught us a lot of good lessons.


Swaminath A, Parpia S, Wierzbicki M, et al. LUSTRE: a phase III randomized trial of stereotactic body radiotherapy (SBRT) vs. conventionally hypo fractionated radiotherapy (CRT) for medically inoperable stage I non-small cell lung cancer (NSCLC). Presented at 2022 American Society for Radiation Oncology Annual Meeting (ASTRO); October 23-26, 2022; San Antonio, TX. Abstract LBA 08. Accessed November 4, 2022.

Related Videos
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
The toxicity profile of tislelizumab also appears to look better compared with chemotherapy in metastatic esophageal squamous cell carcinoma.
Patients with unresectable or metastatic esophageal squamous cell carcinoma and higher PD-L1 expression may benefit from treatment with tislelizumab, according to Syma Iqbal, MD.
Quantifying disease volume to help identify potential recurrence following surgery may be a helpful advance, according to Sean Dineen, MD.
Sean Dineen, MD, highlights the removal of abdominal wall lesions and other surgical strategies that may help manage symptoms in patients with cancer.
Two women in genitourinary oncology discuss their experiences with figuring out when to begin a family and how to prioritize both work and children.
Over the past few decades, the prostate cancer space has evolved with increased funding for clinical trial creation and enrollment.
Data highlight that patients who are in Black and poor majority areas are less likely to receive liver ablation or colorectal liver metastasis in surgical cancer care.
Findings highlight how systemic issues may impact disparities in outcomes following surgery for patients with cancer, according to Muhammad Talha Waheed, MD.
Related Content